AMLo Biosciences’ Post

AMLo Biosciences are concerned to read that there has been a considerable increase in the incidence of cutaneous malignant #melanoma amongst the elderly in the US. Epidemiological data analysis showed a 2.8-fold increase in incidence from 1987–1991 to 2012–2016 with rates peaking at 1.53 per 1,000 for men and 0.59 per 1,000 for women aged 85+. It is hoped that this evidence will help in the development of strategies for prevention and management of melanoma in the elderly. https://bit.ly/40LKrlE Our prognostic biomarker technology #AMBLor, which accurately stratifies early-stage melanomas at low risk of metastases, can play an important role in understanding which patients could benefit from personalised therapy approaches. Those at low risk of their melanoma progressing could avoid further invasive diagnostic procedures and lengthy follow-ups. This would be particularly beneficial for elderly patients who often have trouble travelling to appointments and find it harder to recover from interventions. https://lnkd.in/eRCcZvNG AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor has received its UKCA mark in the UK. www.amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

A Danish study that followed the post-diagnostic outcomes of over 25,000 #melanoma patients concluded that the American Joint Committee on Cancer Eighth Edition (AJCC8) staging system “did not accurately reflect an increasing risk of recurrence and mortality”. The authors state that there is a need for new tools for risk stratification. https://bit.ly/3W7prCx #AMBLor®, our recently developed prognostic test, enables stratification of individuals with early-stage melanomas that are at low-risk of progression, leading to more appropriate follow-up and personalised management. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers #HealthcareInnovation

The US annual direct healthcare expenditure for individuals with melanoma was around $13.56 billion between 2011 to 2020. This national study found that the marginal total expenditures in the #melanoma cohort were $2,844.75 greater compared with the non-melanoma skin cancer cohort. The majority of the costs relate to doctor visits and hospital stays. bit.ly/41eDt98 Here at AMLo Biosciences we understand the financial burden of melanoma management. #AMBLor our prognostic test, enables risk stratification of individual melanomas leading to more appropriate follow-up for patients at low risk of disease progression and consequently offers the potential for cost savings as well as easing patient anxiety and supporting personalised management. amlo-biosciences.com   AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor ® has received its UKCA mark in the UK. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers 

What if…clinicians could help alleviate the fear of recurrence in melanoma patients? Throughout #MelanomaMay, we have shared a number of visuals highlighting the sometimes debilitating effect that anxiety plays in #melanoma. From fearing scans and procedures to worrying about the return of a melanoma, patients experience anxiety at many levels. Patients can experience such high levels of stress that they may not be able to work or look after their family. Many feel they are not able to plan for their future and anxiety affects their relationships. Here at AMLo Biosciences we have developed our #AMBLor technology to help address patient anxiety associated with a melanoma diagnosis. This technology accurately identifies early-stage melanomas that are at low risk of progression. This means that clinicians may offer a reduced follow-up schedule and can provide some reassurance to these patients that their melanoma is unlikely to progress. www.amlo-biosciences.com AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancer research #biomarkers #knowyourskin

AMLo Biosciences are delighted to read this news about the partnership between the ABPI and the UK government. With the additional funding and the creation of further clinical trial hubs, it will mean patients receive access to new treatments faster. https://bit.ly/3zfFhmr We would like to see this investment extended further to include #diagnostics and #prognostics. With advancements in these technologies, patients can get diagnosed without delay, their disease prognosis fully understood, and their treatment and management tailored to their individual needs. Our prognostic #melanoma biomarker #AMBLor accurately identifies early-stage melanomas at low risk of progression. We are proud that it successfully received its UKCA mark last week and is now available to healthcare professionals. But this is just the beginning. Our test needs to be incorporated into clinical practice to be able to benefit melanoma patients, as well as utilise and free-up valuable healthcare resources. Read more: https://bit.ly/479VHJK #dermatology #dermatopathology #histopathology #histology #oncology #skincancer #cancerresearch #biomarkers #healthinvestment

AMLo Biosciences are excited to read in Precision Oncology that the University of Michigan have discovered a prognostic #biomarker that could help to identify renal cancers at high risk of recurrence. https://bit.ly/3LlBEhi The lead author notes that, “We need biomarkers to identify and better treat those who need to be treated and avoid treatment in those that do not need to be treated.” Similarly, our biomarker technology, #AMBLor, can accurately identify early-stage #melanomas at low-risk of progression using the skin samples taken at the staging biopsy. This additional prognostic information can risk-stratify melanomas helping clinical decision makers with personalised disease management and follow-up. www.amlo-biosciences.com   AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. The AMBRA1 and loricrin test is available in the UK as a UKAS accredited LDT #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers  

The UK government has announced its ambitious plan to reduce NHS waiting lists by expanding access to Community Diagnostic Centres and surgical hubs. This initiative aims to provide quicker, more convenient care, and could particularly benefit #melanoma patients.  https://bit.ly/4hlVgjx The BBC article states, “one million unnecessary appointments per year will be freed up for patients who need them. This will be made possible by abolishing automatic review appointments after treatment and only offering them to patients who request them.” AMLo Biosciences feel that our #AMBLor biomarker diagnostic test, which accurately segments early-stage melanoma patients at low risk of progression, could play a major role in achieving this target and improving patient outcomes. By incorporating AMBLor® into standard melanoma diagnostic practice, this can reduce the need for additional invasive diagnostic procedures and lengthy follow-up schedules, thereby freeing appointment times and significantly easing the burden on our healthcare system. AMBLor® received its UKCA mark in 2024. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers Chi Onwurah Helen Huitson

Microbiome derived biotherapeutics. Microviable Therapeutics SL Microbiome based therapeutics to address unmet challenges in human health. Providing novel solution into infectious diseases, oncology and dermatology. This is the core of our company. We unravel the key features of human commensal bacteria to develop bacterial consortia and complete microbiota ecosystem products generating novel biological drugs and microbiome therapies. We develop this biotherapeutics internally in our state of the art facilities from early stage R&D, with our unique expertise in anaerobic bacteria, to GMP manufacturing to bring our products into clinical trials. More information: https://lnkd.in/dZFjv_83 #microbiome #biotherapeutics #gutmicrobiota #infectiousdiseases #oncology #dermatology #microbiometherapies #biologicaldrugs #bacterialconsortia #LBPs

Radiopharmaceuticals are transforming the future of targeted cancer treatment, and OncoBeta is at the heart of this dynamic and high-growth category. By harnessing isotopes like rhenium-188, we are developing next-generation therapies that deliver precise, localised treatment with minimal impact on healthy tissues. Radiopharmaceuticals offer scalable opportunities across various cancer types, enabling treatments that are innovative, effective and offers improved patient outcomes. As global interest in #radiopharmaceuticals surges, OncoBeta is at the forefront with pioneering therapies that leverage the clinical applications of suitable isotopes. With our focus on advancing these therapies, OncoBeta is uniquely positioned for growth in this rapidly expanding market. Visit the website: https://lnkd.in/ejR4d-qW #OncoBeta #Rhenium188 #TreatingNMSC #SkinCancer #NonMelanomaSkinCancer #BCC #SCC #SkinCancerTreatment #Painless #NonInvasive #SingleSession #Aesthetic #EpidermalRadioisotopeTherapy #NuclearMedicine #Dermatology #Personalised #Precision

Today marks World Cancer Research Day! Every year #WCRD highlights the transformative power of cancer research in advancing prevention, diagnosis, and treatment that increase survival and reduce the global cancer burden. Cancer is projected to become the leading cause of death worldwide, with an increase to 21.6 million new cases per year predicted by 2030. https://lnkd.in/d3sCkBs AMLo Biosciences are proud to be part of the cancer research movement to improve #melanoma management. Our innovative prognostic biomarker test, #AMBLor, can accurately identify early-stage patients at low risk of progression. This enables patients to be spared invasive procedures and lengthy follow-ups, meaning valuable healthcare resources and physician time can be better utilised. #WorldCancerResearchDay #WCRD2024 #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers